New Guidelines and Recommendations to Advance Treatment Planning in Proton Therapy

Overview

Journal Phys Imaging Radiat Oncol

Date 2025 Jan 27

PMID 39866245

Authors

Barbara Knausl

Anne Vestergaard

Marco Schwarz

Ludvig P Muren

Affiliations

Soon will be listed here.

References

Hansen C, Jensen K, Smulders B, Sander Holm A, Samsoe E, Nielsen M . Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35. Radiother Oncol. 2023; 190:109812. DOI: 10.1016/j.radonc.2023.109812. View

Clark C, Jornet N, Muren L . The role of dosimetry audit in achieving high quality radiotherapy. Phys Imaging Radiat Oncol. 2021; 5:85-87. PMC: 7807592. DOI: 10.1016/j.phro.2018.03.009. View

Peeler C, Mirkovic D, Titt U, Blanchard P, Gunther J, Mahajan A . Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. Radiother Oncol. 2016; 121(3):395-401. PMC: 5450501. DOI: 10.1016/j.radonc.2016.11.001. View

Langendijk J, Orecchia R, Haustermans K, Zips D, Balosso J, Lacombe D . Prospective data registration and clinical trials for particle therapy in Europe. Radiother Oncol. 2018; 128(1):9-13. DOI: 10.1016/j.radonc.2018.06.001. View

Fusella M, Alvarez Andres E, Villegas F, Milan L, Janssen T, Dal Bello R . Results of 2023 survey on the use of synthetic computed tomography for magnetic resonance Imaging-only radiotherapy: Current status and future steps. Phys Imaging Radiat Oncol. 2024; 32:100652. PMC: 11460247. DOI: 10.1016/j.phro.2024.100652. View

Zhang Y, Trnkova P, Toshito T, Heijmen B, Richter C, Aznar M . A survey of practice patterns for real-time intrafractional motion-management in particle therapy. Phys Imaging Radiat Oncol. 2023; 26:100439. PMC: 10133874. DOI: 10.1016/j.phro.2023.100439. View

Goma C, Henkner K, Jakel O, Lorentini S, Magro G, Mirandola A . ESTRO-EPTN radiation dosimetry guidelines for the acquisition of proton pencil beam modelling data. Phys Imaging Radiat Oncol. 2024; 31:100621. PMC: 11364130. DOI: 10.1016/j.phro.2024.100621. View

Taasti V, Hattu D, Peeters S, van der Salm A, van Loon J, De Ruysscher D . Clinical evaluation of synthetic computed tomography methods in adaptive proton therapy of lung cancer patients. Phys Imaging Radiat Oncol. 2023; 27:100459. PMC: 10314284. DOI: 10.1016/j.phro.2023.100459. View

Pfaehler E, Zhovannik I, Wei L, Boellaard R, Dekker A, Monshouwer R . A systematic review and quality of reporting checklist for repeatability and reproducibility of radiomic features. Phys Imaging Radiat Oncol. 2021; 20:69-75. PMC: 8591412. DOI: 10.1016/j.phro.2021.10.007. View

10.

Taasti V, Hazelaar C, Vaassen F, Vaniqui A, Verhoeven K, Hoebers F . Clinical implementation and validation of an automated adaptive workflow for proton therapy. Phys Imaging Radiat Oncol. 2022; 24:59-64. PMC: 9525894. DOI: 10.1016/j.phro.2022.09.009. View

11.

Friborg J, Jensen K, Eriksen J, Samsoe E, Maare C, Farhadi M . Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer. Radiother Oncol. 2023; 190:109958. DOI: 10.1016/j.radonc.2023.109958. View

12.

Wagenaar D, Habraken S, Rinaldi I, Eekers D, Kramer M, Jaspers J . Evaluating and reporting LET and RBE-weighted dose in proton therapy for glioma - The Dutch approach. Radiother Oncol. 2024; 202:110653. DOI: 10.1016/j.radonc.2024.110653. View

13.

Truelsen C, Ronde H, Kallehauge J, Poulsen L, Havelund B, Pedersen B . Inter-fraction motion robustness in a prospective phase II trial on dose-escalated proton reirradiation for locally recurrent rectal cancer. Phys Imaging Radiat Oncol. 2024; 31:100634. PMC: 11402650. DOI: 10.1016/j.phro.2024.100634. View

14.

Guan F, Bronk L, Kerr M, Li Y, Braby L, Sobieski M . Interpreting the biological effects of protons as a function of physical quantity: linear energy transfer or microdosimetric lineal energy spectrum?. Sci Rep. 2024; 14(1):25181. PMC: 11502811. DOI: 10.1038/s41598-024-73619-x. View

15.

Arscott W, Thompson R, Yin L, Burgdorf B, Kirk M, Ben-Josef E . Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications. Phys Imaging Radiat Oncol. 2021; 8:17-22. PMC: 7807648. DOI: 10.1016/j.phro.2018.11.004. View

16.

Guida F, Barbato A, Ciocca M, Schwarz M, Lorentini S, Mastella E . Dose intercomparison at Italian hadrontherapy centers. Phys Med. 2019; 68:83-87. DOI: 10.1016/j.ejmp.2019.11.009. View

17.

Stick L, Lorenzen E, Yates E, Anandadas C, Andersen K, Aristei C . Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. Clin Transl Radiat Oncol. 2021; 27:126-131. PMC: 7892790. DOI: 10.1016/j.ctro.2021.01.012. View

18.

Taylor S, Lim P, Ahmad R, Alhadi A, Harris W, Rompokos V . Risk of radiation-induced second malignant neoplasms from photon and proton radiotherapy in paediatric abdominal neuroblastoma. Phys Imaging Radiat Oncol. 2021; 19:45-52. PMC: 8295851. DOI: 10.1016/j.phro.2021.06.003. View

19.

Weber D, Langendijk J, Grau C, Thariat J . Proton therapy and the European Particle Therapy Network: The past, present and future. Cancer Radiother. 2020; 24(6-7):687-690. PMC: 7395642. DOI: 10.1016/j.canrad.2020.05.002. View

20.

Weber D, Grau C, Lim P, Georg D, Lievens Y . Bringing Europe together in building clinical evidence for proton therapy - the EPTN-ESTRO-EORTC endeavor. Acta Oncol. 2019; 58(10):1340-1342. DOI: 10.1080/0284186X.2019.1624820. View